Jin Shu

Prolonged and tunable residence time using reversible covalent kinase inhibitors

J. Michael Bradshaw, Jesse M. McFarland, Ville O. Paavilainen et al. · Nature Chemical Biology · 2015 · 422 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +5

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

Claire L. Langrish, J. Michael Bradshaw, Michelle Francesco et al. · The Journal of Immunology · 2021 · 108 citations · Full text

Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (PRN1371) for the Treatment of Solid Tumors

Ken A. Brameld, Timothy D. Owens, Erik Verner et al. · Journal of Medicinal Chemistry · 2017 · 95 citations · Full text

Drug Target, Solid Tumors, Pharmacotherapy +20

Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)

Timothy D. Owens, Ken A. Brameld, Erik Verner et al. · Journal of Medicinal Chemistry · 2022 · 65 citations · Full text

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

Timothy D. Owens, Patrick F. Smith, Andrew Redfern et al. · Clinical and Translational Science · 2021 · 47 citations · Full text

Chemoprevention Strategy, Tyrosine Kinase, Immunology +20